drugset / Trial / NCT07524920
Comparing Efficacy and Safety of (Meropenem + Colistin) Versus (Imipenem/Cilastatin + Tigecycline) on Eradication of Multi-Drug Resistance Bacteria
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aims to compare the efficacy and safety of two antibiotic combinations (Colistin + Meropenem) vs (Imipenem/cilastatin+ Tigecycline) in the treatment of adults with MDR gram-negative infections.
Timeline
- Start
- 2026-04-01
- Primary completion
- 2026-08-01
- Completion
- 2026-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Colistin | Other / unclassified | 5e+06 iu | Intravenous |
| Subject | Imipenem/cilastatin | Unknown | 500 mg | — |
| Subject | Imipenem/cilastatin | Unknown | 1 g | — |
| Subject | Meropenem | Small molecule | 2 g | Intravenous |
| Subject | Tigecycline | Small molecule | 100 mg | — |